Home > Annual Financials > BALAXI PHARMACEUTICALS

BALAXI PHARMACEUTICALS Financial Statement Analysis
[NSE : BALAXI]

The Revenues of BALAXI PHARMACEUTICALS have increased by 20.42% YoY .
The Earnings Per Share (EPS) of BALAXI PHARMACEUTICALS has decreased by Negative YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

BALAXI PHARMACEUTICALS Last 5 Annual Financial Results
[NSE : BALAXI]

ConsolidatedMar2024
Mar2023
Mar2022
Mar2021
Mar2020
Revenues ₹336 Cr₹279 Cr₹231 Cr₹46 Cr₹1,360 Cr
Expenses ₹279 Cr₹229 Cr₹189 Cr₹37 Cr₹1,204 Cr
Operating Profit (Excl OI) ₹57 Cr₹51 Cr₹43 Cr₹8.25 Cr₹156 Cr
Other Income ₹2.64 Cr₹4.97 Cr₹2.23 Cr₹0.60 Cr₹89 Cr
Interest ₹1.38 Cr₹0.76 Cr₹0.28 Cr₹0.05 Cr₹0.23 Cr
Depreciation ₹1.75 Cr₹0.51 Cr₹0.30 Cr₹0.01 Cr₹0.35 Cr
Profit Before Tax ₹57 Cr₹55 Cr₹44 Cr₹8.79 Cr₹244 Cr
Profit After Tax ₹46 Cr₹48 Cr₹38 Cr₹6.10 Cr₹197 Cr
Consolidated Net Profit ₹52 Cr₹48 Cr₹37 Cr₹6.13 Cr₹197 Cr
Earnings Per Share (Rs)₹-6.70₹50.82₹48.18₹37.23₹6.13
PAT Margin (%)-0.9913.6617.0616.4913.38
ROE(%)-1.2932.1753.5082.2639.04
ROCE(%)2.3137.4659.6292.5656.56
Total Debt/Equity(x)0.090.070.030.060.00

Key Financials

Market Cap : ₹ 412.5 Cr
Revenue (TTM) : ₹ 263.6 Cr
Net Profit(TTM) : ₹ 35.6 Cr
EPS (TTM) : ₹ 6.4
P/E (TTM) : 11.6

Industry Peers & Returns1W1M1Y
BALAXI PHARMACEUTICALS -8.7% -1.2% -9.5%
ADANI ENTERPRISES -6.6% 7.4% -18.8%
REDINGTON -4% 7.4% 18.4%
HONASA CONSUMER 4.6% 9.5% -36.8%
MMTC -4.3% 0.9% 24.5%
MSTC -10.6% 9.2% 38.4%
LLOYDS ENTERPRISES -7.5% 4.1% 16.2%
VERITAS (INDIA) -2.9% 12.8% 117.9%
NOVARTIS INDIA -3.7% -5% 39%


BALAXI PHARMACEUTICALS Revenues
[NSE : BALAXI]

Y-o-Y

20.42 %

5 Yr CAGR

-29.47 %

Years Revenues % Change
Mar2024 ₹336 Cr
20.42
Mar2023 ₹279 Cr
20.77
Mar2022 ₹231 Cr
406.94
Mar2021 ₹46 Cr
-96.64
Mar2020 ₹1,360 Cr -


BALAXI PHARMACEUTICALS Operating Profit
[NSE : BALAXI]

Y-o-Y

12.97 %

5 Yr CAGR

-22.09 %

Years Operating Profit % Change
Mar2024 ₹57 Cr
12.97
Mar2023 ₹51 Cr
19.08
Mar2022 ₹43 Cr
417.06
Mar2021 ₹8.25 Cr
-94.70
Mar2020 ₹156 Cr -

Operating Margins
Y-o-Y

-6.16 %

5 Yr CAGR

10.47 %

Years Operating Margin% % Change
Mar2024 17.07%
-6.16
Mar2023 18.19%
-1.41
Mar2022 18.45%
1.99
Mar2021 18.09%
57.85
Mar2020 11.46% -

BALAXI PHARMACEUTICALS Profit After Tax
[NSE : BALAXI]

Y-o-Y

7.39 %

5 Yr CAGR

-28.37 %

Years Profit After Tax % Change
Mar2024 ₹52 Cr
7.39
Mar2023 ₹48 Cr
29.41
Mar2022 ₹37 Cr
507.51
Mar2021 ₹6.13 Cr
-96.88
Mar2020 ₹197 Cr -

PAT Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years PAT Margin(%) % Change
Mar2024 -0.99 %
Negative
Mar2023 13.66 %
-19.93
Mar2022 17.06 %
3.46
Mar2021 16.49 %
23.24
Mar2020 13.38 % -

BALAXI PHARMACEUTICALS Earnings Per Share (EPS)
[NSE : BALAXI]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years EPS % Change
Mar2024 ₹-6.70
Negative
Mar2023 ₹51
5.48
Mar2022 ₹48
29.41
Mar2021 ₹37
507.34
Mar2020 ₹6.13 -

BALAXI PHARMACEUTICALS Return on Capital Employed (ROCE)
[NSE : BALAXI]

Y-o-Y

-93.83 %

5 Yr CAGR

-55.05 %

Years ROCE % Change
Mar2024 2.31%
-93.83
Mar2023 37.46%
-37.17
Mar2022 59.62%
-35.59
Mar2021 92.56%
63.65
Mar2020 56.56% -

BALAXI PHARMACEUTICALS Share Price vs Sensex

Current Share Price : ₹74.7
Current MarketCap: ₹ 412.5 Cr
Updated EOD on :Dec 20,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
BALAXI PHARMACEUTICALS

-8.7%

-1.2%

-9.5%

SENSEX

-5%

0.6%

9.2%

BALAXI PHARMACEUTICALS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about BALAXI PHARMACEUTICALS Financials


How the annual revenues of BALAXI PHARMACEUTICALS have changed ?

The Revenues of BALAXI PHARMACEUTICALS have increased by 20.42% YoY .

How the Earnings per Share (EPS) of BALAXI PHARMACEUTICALS have changed?

The Earnings Per Share (EPS) of BALAXI PHARMACEUTICALS has decreased by Negative YoY .